• Mr. Umesh Kumar Chaurasiya
• Mr. Mahendra Ahirwar
• Mr. Shubham Chaurasia
• Mr. Ashish Verma

The controlled release of pharmacologically active agents to specific site of action at the therapeutically optimal rate and dose regimen has been a major goal in designing such devices. BBB (Blood brain barrier) represents an insurmountable barrier for the majority of drugs including anticancer agents, antibiotics, peptides and other oligo and macromolecular drugs. The limited access of these drugs to the brain is due to the tight junctions between the endothelial cells lining the brain blood vessels as well as to the existence of very active drug transport systems e.g. the ABC-transporters (ATP-binding cassette transporters such as Pgp) in the luminal cell membrane of these cells. The tight junctions prevent all paracellular drug transport whereas the ABC transporters immediately transport drugs that have partitioned into the endothelial cell membranes back into the blood stream. A number of strategies have been developed to overcome this problem including the employment of pro-drugs, opening of the tight junctions using hyperosmolaric solutions, or drug carrier systems such as antibodies, liposomes, or nanocarriers and intranasal as delivery route.

Rivastigmine, Intranasal Drug Delivery System, Alzheimer’s Disease,

"Formulation and Characterization of Rivastigmine Intranasal Drug Delivery System for the Treatment of Alzheimer’s Disease", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.11, Issue 12, page no.b144-b160, December-2024, Available :http://www.jetir.org/papers/JETIR2412106.pdf

"Formulation and Characterization of Rivastigmine Intranasal Drug Delivery System for the Treatment of Alzheimer’s Disease", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.11, Issue 12, page no. ppb144-b160, December-2024, Available at : http://www.jetir.org/papers/JETIR2412106.pdf